Association of African-American Ethnic Background With Survival in Men With Metastatic Prostate Cancer
Ian M. Thompson, Catherine M. Tangen, Anthony Tolcher, E. David Crawford, Mario Eisenberger, Carol M. Moinpour Affiliations of authors: I. M. Thompson, A. Tolcher, The University of Texas Health Sciences Center at San Antonio; C. M. Tangen, C. M. Moinpour, The Southwest Oncology Group Statistical Center, Seattle, WA; E. D. Crawford, The University of Colorado Health Sciences Center, Denver; M. Eisenberger, The Johns Hopkins University, Baltimore, MD.
Correspondence to: Ian M. Thompson, M.D., Division of Urology, The University of Texas Health Sciences Center at San Antonio, MC 7845, 7703 Floyd Curl Dr., San Antonio, TX 78229–3900 (e-mail: firstname.lastname@example.org).Reprint requests to: Southwest Oncology Group (SWOG-8894), Operations Office, 14980 Omicron Dr., San Antonio, TX 78245–3217.
Background: African-American men have earlier onset of prostate cancer, higher prostate-specific antigen (PSA) levels, more advanced stage at diagnosis, and higher mortality than white men. It is not known whether the poorer survival of African-American men with prostate cancer reflects their later stage at diagnosis or differences in the basic biology of their disease.
To evaluate this question, we examined outcomes of African-American and white men with metastatic prostate cancer in the context of a randomized clinical trial.
Methods: Southwest Oncology Group Study 8894 was a randomized phase III trial that compared orchiectomy with or without flutamide in men with metastatic prostate cancer. Using data from 288 African-American and 975 white men in the trial, we conducted a proportional hazards regression analysis to determine if ethnicity was an independent predictor of survival. All statistical tests were two-sided.
Results: African-American men were more likely than white men to have extensive disease and bone pain and had poorer performance status, younger age at study entry, higher Gleason score, and higher PSA levels. After adjustment for these prognostic variables, the hazard ratio (HR) for all-cause mortality for African-American men relative to white men was 1.23 (P = .018).
Further adjustment for initial quality-of-life assessments also resulted in higher HRs associated with African-American ethnicity relative to white ethnicity (HR = 1.39; P = .007). Conclusions: African-American men with metastatic prostate cancer have a statistically significantly worse prognosis than white men that cannot be explained by the prognostic variables explored in this study.
These data should give increased impetus for efforts to detect the disease early in African-American men and for the development of more effective therapies based on potential biologic differences in this ethnic group.
Journal of the National Cancer Institute, Vol. 93, No. 3, 219-225, February 7, 2001
Proceedings of the Nat Academy of Sciences, 8/04
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.